Page 3 - Tolerability Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomBrian stuglikRachel grishamNate liabraatenDan calkinsElisa buffingtonSusana banerjeeChugai pharmaceutical co ltdNational cancer instituteEuropean network for gynaecological oncological trialRaf and mek programEuropean network of gynaecological oncological trialInstitute of cancer researchCompany intends to file for accelerated

Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer

Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). These findings further validate the safety and tolerability profile of FHD-286. However, Foghorn does not intend to pursue FHD-286 to treat uveal melanoma. The Phase 1 dose-escalation study of FHD-286 in metastatic uveal melanoma included 73 patients who had received a median of two prior therapies across nine different cohorts. The clinical data

Foghorn therapeutics incBenzinga proFoghorn therapeutics shifts focusDevelopment of cancer hopefulEye cancerUveal melanomaDose escalationTolerability profileClinical dataTumor microenvironmentCombination treatmentArget lesionsMyelodysplastic syndromeClinical activity

Kinnate Biopharma : Results of Operations and Financial Condition - Form 8-K

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a. | April 17, 2023

United statesPriyanka shahRichard williamsAlexander spiraNima farzanVirginia cancer specialists research instituteKinnate biopharma incExchange commissionAmerican association for cancer researchFirst reportInvestigational exarafenibSingle agentClinical trials mini symposium sessionAmerican associationCancer researchVirginia cancer specialists research

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine regan lindenboomParag kaleJosh brodskyRenan denoncourtYork heart associationFranchise lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incHealth statusExchange commissionAlnylam pharmaceuticalsEuropean unionWall streetNew data further support potential

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.